Jaguar Health Stock (NASDAQ:JAGX)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.06

52W Range

$0.95 - $30.84

50D Avg

$1.17

200D Avg

$4.59

Market Cap

$9.61M

Avg Vol (3M)

$314.71K

Beta

0.84

Div Yield

-

JAGX Company Profile


Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

49

IPO Date

May 12, 2015

Website

JAGX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Mytesi$9.60M$11.70M$3.30M
Neonorm$42.00K$48.00K$62.00K

Fiscal year ends in Dec 23 | Currency in USD

JAGX Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.76M$11.96M$4.33M
Operating Income$-34.29M$-34.41M$-39.07M
Net Income$-41.30M$-47.45M$-60.25M
EBITDA$-34.29M$-31.17M$-39.66M
Basic EPS-$-36.18$-101.07
Diluted EPS-$-36.18$-101.07

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 13, 24 | 2:57 PM
Q1 24May 14, 24 | 12:00 AM
Q4 23Apr 01, 24 | 10:47 AM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
GOVXGeoVax Labs, Inc.
VIRIVirios Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
TNXPTonix Pharmaceuticals Holding Corp.
VBIVVBI Vaccines Inc.
DFFNCervoMed Inc.
EFTReFFECTOR Therapeutics, Inc.
VXRTVaxart, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
ONTXTraws Pharma, Inc.
ACSTAcasti Pharma Inc.
OCGNOcugen, Inc.
ZURAZura Bio Limited
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.